Results 21 to 30 of about 53,085 (229)

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group

Haematologica, 2020
New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce disease recurrence and treatment-related morbidity. The Children’s Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib to standard ...
Richard Aplenc, Soheil Meshinchi, Lillian Sung, Todd Alonzo, John Choi, Brian Fisher, Robert Gerbing, Betsy Hirsch, Terzah Horton, Samir Kahwash, John Levine, Michael Loken, Lisa Brodersen, Jessica Pollard, Susana Raimondi, Edward Anders Kolb, Alan Gamis   +16 more
doaj   +1 more source

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

Haematologica, 2014
Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules.
María-Victoria Mateos, Sara Bringhen, Paul G. Richardson, Juan Jose Lahuerta, Alessandra Larocca, Albert Oriol, Mario Boccadoro, Ramón García-Sanz, Francesco Di Raimondo, Dixie-Lee Esseltine, Helgi van de Velde, Avinash Desai, Anil Londhe, Jesús F. San Miguel, Antonio Palumbo   +14 more
doaj   +1 more source

Bortezomib

Reactions Weekly, 2012
Hoofnagle JH.
europepmc   +3 more sources

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma

Translational Oncology, 2017
Increased levels of the nuclear export protein, exportin 1 (XPO1), were demonstrated in multiple myeloma (MM) patients. Targeting XPO1 with selinexor (the selective inhibitor of nuclear export; SINE compound KPT-330) demonstrates broad antitumor activity
Barbara Muz, Feda Azab, Pilar de la Puente, Yosef Landesman, Abdel Kareem Azab   +4 more
doaj   +1 more source

Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence

Health Science Reports, 2023
Background and Aims Nonsmall cell lung cancer accounts for over 85% of lung cancer incidences worldwide, and often has a poor prognosis. Proteasome inhibitors, such as bortezomib, have previously demonstrated evidence in preclinical and clinical models ...
Alethea Dasha Wenning Chua, Thirumeninathan Thaarun, Hui Yang, Ainsley Ryan Yan Bin Lee   +3 more
doaj   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Bortezomib alters sour taste sensitivity in mice

Toxicology Reports, 2017
Chemotherapy-induced taste disorder is one of the critical issues in cancer therapy. Bortezomib, a proteasome inhibitor, is a key agent in multiple myeloma therapy, but it induces a taste disorder.
Akihiro Ohishi, Kentaro Nishida, Karin Miyamoto, Mizuka Imai, Ryoko Nakanishi, Kyoko Kobayashi, Akiko Hayashi, Kazuki Nagasawa   +7 more
doaj   +1 more source

Bortezomib in combination with standard-of-care for late active antibody-mediated rejection with de novo donor-specific antibodies after kidney transplantation: a multicenter randomized trial [PDF]

Transpl Int
Snanoudj R, Marquant F, Renaudin K, Dubois V, Koenig A, Arzouk N, Caillard S, Giral M, Jalal Eddine A, Mazouz H, Kamar N, Pernin V, Matignon M, Ouali N, Anglicheau D, Elie C.   +15 more
europepmc   +2 more sources

A role for eIF5A in translational control of stress‐inducible proteins in multiple myeloma cell lines

Molecular Oncology, EarlyView.
Loss of eIF5A rewires thapsigargin‐mediated endoplasmic reticulum stress responses in multiple myeloma cells by selective translation of mRNA transcripts, consequently dampening thapsigargin‐induced unfolded protein response (UPR) activation and shifting the balance from induction of apoptosis toward cell survival and proliferation.
Demi Both, Ingrid A. M. Derks, Raphaël Vanleyssem, Marine Leclercq, Najla El Hachem, Pierre Close, Eric Eldering, Marco Vincent Haselager   +7 more
wiley   +1 more source

Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis

Blood Cancer Journal
Induction regimens for multiple myeloma (MM) commonly include bortezomib, which has typically been administered twice weekly despite studies demonstrating comparable efficacy and less peripheral neuropathy (PN) with once-weekly bortezomib.
Fieke W. Hoff, Rahul Banerjee, Adeel M. Khan, Georgia McCaughan, Bo Wang, Xiaoliang Wang, James Roose, Larry D. Anderson, Andrew J. Cowan, S. Vincent Rajkumar, Gurbakhash Kaur   +10 more
doaj   +1 more source